# GYRE catalysts: GYRE THERAPEUTICS, INC. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/gyre/catalysts

> GYRE THERAPEUTICS, INC. (GYRE) has 1 upcoming catalyst. The next is the CG923308 trial start, mid-2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for GYRE?

GYRE THERAPEUTICS, INC. (GYRE) has 1 upcoming catalyst. The next is the CG923308 trial start, mid-2027. Press release filed with the SEC (EX-99): "Gyre expects to submit Investigational New Drug (IND) applications and initiate Phase 1 clinical trials, upon regulatory approval of IND applications, in the United States and/or China around mid-2027 for CG923308, a CDK2-Cyclin E dual degrader for solid tumor indications, and CG620953, a TYK2-JAK1 dual degrader for autoimmune diseases." [Calendar and source filings](https://sec-api.dev/companies/gyre/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001193125-26-449985, https://www.sec.gov/Archives/edgar/data/1124105/000119312526449985/gyre-ex99_1.htm (retrieved 2026-11-12). Last confirmed 2026-11-05. Cite: https://sec-api.dev/companies/gyre/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | GYRE THERAPEUTICS, INC. |
| Ticker | GYRE (Nasdaq) |
| SEC CIK | 1124105 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/gyre |

## Cash runway

Cash $59.0M as of 2026-09-30; quarterly burn $4.0M; about 44.5 months of runway at that rate (XBRL company facts, accession 0001193125-26-450334).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Oct 2024 | [GYRE THERAPEUTICS, INC. topline data readout](https://sec-api.dev/companies/gyre/catalysts) | GYRE |  | completed, met | "Current Status Phase 3 trial of CHB currently on-going in China; Last patient completed treatment Oct 2024; Reported positive topline data in Q2 2025 — met primary endpoint." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1124105/000114036126007249/ex20066398_ex99-2.htm)) |
| Oct 2024 | [GYRE THERAPEUTICS, INC. topline data readout](https://sec-api.dev/companies/gyre/catalysts) | GYRE |  | completed, met | "Last patient completed treatment Oct 2024; Reported positive topline data in Q2 2025 — met primary endpoint." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1124105/000114036126023625/ef20075381_ex99-1.htm)) |
| November 13, 2024 | [GYRE THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/gyre/catalysts) | GYRE |  | completed | "Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1124105/000095017024125869/gyre-ex99_1.htm)) |
| Jan 2025 | [CG001419 trial start](https://sec-api.dev/pdufa/cg001419) | GYRE |  | completed | "In addition, in January 2025, Cullgen began the Phase 1 clinical trial in Australia for acute and chronic pain." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1124105/000114036125004957/ny20043721x1_ex99-1.htm)) |
| Q1 2025 | [Entecavir topline data readout](https://sec-api.dev/pdufa/entecavir) | GYRE |  | scheduled | "Gyre Pharmaceuticals remains on track to report topline data in the first quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1124105/000095017024125869/gyre-ex99_1.htm)) |
| Mar 2025 | [ETUARY® (pirfenidone) trial start](https://sec-api.dev/pdufa/pirfenidone) | GYRE |  | completed | "In addition to IPF, we are pursuing potential label expansion into additional indications in the PRC, including pneumoconiosis, for which, in 2025, we completed enrollment of 272 patients in our 52-week Phase 3 trial, and radiation-induced lung injury ("RILI"), including cases with or without immune-related pneumonitis, for which the National Medical Products Administration ("NMPA") approved our clinical trial application in March 2025, and we initiated an adaptive Phase 2/3 study in April 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1124105/000119312526450334/gyre-20260930.htm)) |
| March 17, 2025 | [GYRE THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/gyre/catalysts) | GYRE |  | completed | "Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1124105/000095017025040232/gyre-ex99_1.htm)) |
| Q2 2025 | [Entecavir topline data readout](https://sec-api.dev/pdufa/entecavir) | GYRE |  | scheduled | "Gyre expects to report topline data in the second quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1124105/000095017025040232/gyre-ex99_1.htm)) |
| Q2 2025 | [Ofev® (nintedanib) topline data readout](https://sec-api.dev/pdufa/nintedanib) | GYRE |  | scheduled | ""In parallel, we expect to share topline data from our pivotal Phase 3 trial in CHB-associated liver fibrosis in the second quarter of 2025, which will help inform our U.S. Phase 2 proof-of-concept trial of F351 in MASH-associated liver fibrosis."" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1124105/000095017025040232/gyre-ex99_1.htm)) |
| Q2 2025 | [ETUARY® (pirfenidone) topline data readout](https://sec-api.dev/pdufa/pirfenidone) | GYRE |  | scheduled | "In addition, Gyre Pharmaceuticals is evaluating F351 in a Phase 3 clinical trial in CHB-associated liver fibrosis in the PRC, which is expected to report topline data by Q2 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1124105/000095017025067452/gyre-ex99_1.htm)) |
| Q2 2025 | [GYRE THERAPEUTICS, INC. topline data readout](https://sec-api.dev/companies/gyre/catalysts) | GYRE |  | scheduled | "Our most significant near-term catalyst is the anticipated topline results of F351 for our ongoing Phase 3 trial in the PRC expected in the second quarter of 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1124105/000095017025040279/gyre-20241231.htm)) |
| Q2 2025 | [GYRE THERAPEUTICS, INC. topline data readout](https://sec-api.dev/companies/gyre/catalysts) | GYRE |  | scheduled | "In October 2024, the last patient completed this 52-week trial and we expect to report topline data from this trial by the second quarter of 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1124105/000095017025040279/gyre-20241231.htm)) |
| May 9, 2025 | [GYRE THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/gyre/catalysts) | GYRE |  | completed | "Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1124105/000095017025067452/gyre-ex99_1.htm)) |
| May 22, 2025 | [Hydronidone topline data readout](https://sec-api.dev/pdufa/hydronidone) | GYRE |  | completed, met | "As previously disclosed on May 22, 2025, Gyre reported topline results from its Phase 3 trial in CHB-associated liver fibrosis demonstrating that Hydronidone met its primary endpoint, with 52.85% of treated patients achieving ≥1-stage fibrosis regression at Week 52, compared with 29.84% in the placebo group (p=0.0002), based on centralized, blinded Ishak histologic assessment." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1124105/000114036126000253/ny20062326x1_ex99-1.htm)) |
| Q3 2025 | [Hydronidone NDA/BLA submission](https://sec-api.dev/pdufa/hydronidone) | GYRE |  | scheduled | "In addition, Gyre Pharmaceuticals remains on track to file an NDA for Hydronidone with the NMPA in the third quarter of 2025 to potentially support our growing commercial portfolio."" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1124105/000095017025106525/gyre-ex99_1.htm)) |
| Q3 2025 | [ETUARY® (pirfenidone) NDA/BLA submission](https://sec-api.dev/pdufa/pirfenidone) | GYRE |  | scheduled | "Based on these results, Gyre intends to file a New Drug Application ("NDA") with the PRC's National Medical Products Administration ("NMPA") in the third quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1124105/000095017025106525/gyre-ex99_1.htm)) |
| 2H 2025 | [Hydronidone trial start](https://sec-api.dev/pdufa/hydronidone) | GYRE | MASH-associated fibrosis | scheduled | "In parallel, the Company is actively preparing to file an investigational new drug ("IND") application in the third quarter of 2025 and, subject to IND clearance, plans to initiate a Phase 2 trial in the U.S. evaluating Hydronidone for the treatment of MASH-associated fibrosis in the second half of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1124105/000114036125020157/ef20048898_ex99-1.htm)) |
| Q3 2025 | [Entecavir NDA/BLA submission](https://sec-api.dev/pdufa/entecavir) | GYRE |  | scheduled | "Based on these positive results, Gyre plans to file an NDA with China's NMPA in the third quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1124105/000114036125020157/ef20048898_ex99-1.htm)) |
| August 5, 2025 | [GYRE THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/gyre/catalysts) | GYRE |  | completed | "Gyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1124105/000095017025106525/gyre-ex99_1.htm)) |
| Q4 2025 | [ETUARY® (pirfenidone) trial start](https://sec-api.dev/pdufa/pirfenidone) | GYRE |  | scheduled | "Plan to initiate an adaptive Phase 2/3 trial of pirfenidone in oncology-related pulmonary complications (RILI/immune-related pneumonitis) in Q4 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1124105/000119312525270524/gyre-ex99_1.htm)) |
| November 7, 2025 | [GYRE THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/gyre/catalysts) | GYRE |  | completed | "Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1124105/000119312525270524/gyre-ex99_1.htm)) |
| 1H 2026 | [Hydronidone NDA/BLA submission](https://sec-api.dev/pdufa/hydronidone) | GYRE | CHB-associated liver fibrosis | scheduled | "Based on these positive results, we currently expect to submit an NDA for conditional approval of Hydronidone in the first half of 2026, subject to final data readiness and applicable regulatory procedures." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1124105/000119312526106251/gyre-20251231.htm)) |
| Mar 2026 | [Hydronidone NDA/BLA submission](https://sec-api.dev/pdufa/hydronidone) | GYRE |  | completed | "The acceptance came after Gyre submitted the NDA through its majority-owned subsidiary Gyre Pharmaceuticals Co., Ltd. (Gyre Pharmaceuticals) following the priority review status for F351 granted by the NMPA in March 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1124105/000119312526449985/gyre-ex99_1.htm)) |
| Mar 2026 | [ETUARY® (pirfenidone) NDA/BLA submission](https://sec-api.dev/pdufa/pirfenidone) | GYRE |  | completed | "In March 2026, Gyre Pharmaceuticals Co., Ltd., submitted its NDA to the CDE to seek conditional approval for F351." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1124105/000119312526209789/gyre-ex99_1.htm)) |
| March 12, 2026 | [GYRE THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/gyre/catalysts) | GYRE |  | completed | "Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1124105/000119312526102700/gyre-ex99_1.htm)) |
| Apr 2026 | [ETUARY® (pirfenidone) trial start](https://sec-api.dev/pdufa/pirfenidone) | GYRE |  | completed | "In April 2026, Gyre Pharmaceuticals initiated its adaptive Phase 2/3 clinical trial in oncology-related pulmonary complications, with the first patient enrolled." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1124105/000119312526449985/gyre-ex99_1.htm)) |
| May 7, 2026 | [GYRE THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/gyre/catalysts) | GYRE |  | completed | "Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1124105/000119312526209789/gyre-ex99_1.htm)) |
| August 7, 2026 | [GYRE THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/gyre/catalysts) | GYRE |  | completed | "Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1124105/000119312526339223/gyre-ex99_1.htm)) |
| late 2026 | [ETUARY® (pirfenidone) trial start](https://sec-api.dev/pdufa/pirfenidone) | GYRE |  | scheduled | "Gyre plans to file an Investigational New Drug (IND) application in the U.S. by the end of 2026, and, if the IND becomes effective, initiate a Phase 2 clinical trial." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1124105/000119312526209789/gyre-ex99_1.htm)) |
| November 5, 2026 | [GYRE THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/gyre/catalysts) | GYRE |  | completed | "Gyre Therapeutics Reports Third Quarter 2026 and Year-to-Date Financial Results with Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1124105/000119312526449985/gyre-ex99_1.htm)) |
| mid-2027 | [CG923308 trial start](https://sec-api.dev/pdufa/cg923308) | GYRE |  | scheduled | "Gyre expects to submit Investigational New Drug (IND) applications and initiate Phase 1 clinical trials, upon regulatory approval of IND applications, in the United States and/or China around mid-2027 for CG923308, a CDK2-Cyclin E dual degrader for solid tumor indications, and CG620953, a TYK2-JAK1 dual degrader for autoimmune diseases." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1124105/000119312526449985/gyre-ex99_1.htm)) |

## Drugs

- [CG001419](https://sec-api.dev/pdufa/cg001419): 
- [CG923308](https://sec-api.dev/pdufa/cg923308): 
- [Entecavir](https://sec-api.dev/pdufa/entecavir): 
- [Hydronidone](https://sec-api.dev/pdufa/hydronidone): chb-associated liver fibrosis, mash-associated liver fibrosis in 2026, mash-associated fibrosis
- [ETUARY® (pirfenidone)](https://sec-api.dev/pdufa/pirfenidone): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/gyre/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "GYRE catalysts: GYRE THERAPEUTICS, INC. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/gyre/catalysts

```bibtex
@misc{secapidev_companies_gyre_catalysts_20261116,
  title        = {GYRE catalysts: GYRE THERAPEUTICS, INC. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/gyre/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_gyre_catalysts_20261116","title":"GYRE catalysts: GYRE THERAPEUTICS, INC. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/gyre/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
